Oxford Biolabs Ltd – Trademark Portfolio

Entity Type: 99

Oxford Biolabs Ltd holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include DRM4, NEA8, MELANIQ, and OXFORD BIOLABS.

The Oxford Science Park,

Robert Robinson Avenue Oxford OX4 4GA

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Oxford Biolabs Ltd's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (5 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

3
Cosmetics & Cleaning (3 filings)

Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring

Frequently Asked Questions

How many trademarks does Oxford Biolabs Ltd have?

Oxford Biolabs Ltd has 5 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 cancelled.

What trademark classes does Oxford Biolabs Ltd file in?

Oxford Biolabs Ltd files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Oxford Biolabs Ltd's most well-known trademarks?

Oxford Biolabs Ltd's registered trademark portfolio includes well-known marks such as DRM4, NEA8, MELANIQ, and OXFORD BIOLABS. These are among 4 currently registered trademarks in the portfolio.

What is Oxford Biolabs Ltd's trademark registration success rate?

Oxford Biolabs Ltd has a 80% trademark registration rate, with 4 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.